Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Sarcoma 7Gliosarcoma 5Glioblastoma 5Brain Neoplasms 4Small Cell Lung Carcinoma 3Oligodendroglioma 3Astrocytoma 3Pancreatic Neoplasms 2Osteosarcoma 2Meningioma 2Medulloblastoma 2Lymphoma 2Lung Neoplasms 2Kidney Neoplasms 2Head and Neck Neoplasms 2Glioma 2Colorectal Neoplasms 2Colonic Neoplasms 2Choroid Plexus Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Wilms Tumor 1Uterine Neoplasms 1Sarcoma, Myeloid 1Sarcoma, Kaposi 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Pinealoma 1

Interventions

surufatinib 1ganitumab 1conatumumab 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Immunotherapy 1Drug Therapy 1Dacarbazine 1Bortezomib 1Biological Therapy 1Biological Factors 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × Bortezomib × Sarcoma × Clear all
NCT00580320 2016-08-18

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Virginia Commonwealth University

Phase 1 Completed
17 enrolled
DermatologicEndocrineHead & NeckSarcomaThoracic

Carcinoid Tumor, Melanoma, Parathyroid Neoplasms, Sarcoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡